<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045979</url>
  </required_header>
  <id_info>
    <org_study_id>1297.8</org_study_id>
    <secondary_id>2013-003722-84</secondary_id>
    <nct_id>NCT02045979</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigate the pharmacokinetics, safety and tolerability of BI695501 and to establish
      pharmacokinetic similarity of BI 695501 to adalimumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Actual">June 20, 2014</completion_date>
  <primary_completion_date type="Actual">June 20, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®.
Abbreviation used: Pharmacokinetics (PK).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
    <description>Area under the concentration time curve from time zero to last measurable concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
    <description>Maximum concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168 hours post dosing</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to 168 hours post dose (AUC 0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312 hours post dosing</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to 312 hours post dose (AUC 0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480 hours post dosing</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to 480 hours post dose (AUC 0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648 hours post dosing</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to 648 hours post dose (AUC 0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032 hours post dosing</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to 1032 hours post dose (AUC 0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira® PK is the abbreviation for Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-∞,Obs of BI 695501, US-licensed Humira® or EU-approved Humira®</measure>
    <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
    <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) based on the last observed concentration at time of last measureable concentration (tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation of Pharmacokinetic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (Proportion) of Subjects With Drug Related Adverse Events</measure>
    <time_frame>Day 1 through Day 71</time_frame>
    <description>All events with an onset after the first administration of the trial medication up to a period of 70 days after the last administration of the trial medication (i.e., end of the REP) was assigned to the treatment phase for evaluation and was defined as a treatment-emergent AE (TEAE). A treatment-related AE was defined as any TEAE assessed by the investigator as related to the trial medication.
All safety data were displayed and analyzed using descriptive statistical methods. No formal inferential analyses were planned for safety comparisons. Tabulations of frequencies and proportions, as appropriate were used for the evaluation of categorical (qualitative) data, and tabulations of descriptive statistics were used to analyze continuous (quantitative) data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 695501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab-EU source</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab-US source</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 695501</intervention_name>
    <description>BI 695501 single s.c. injection</description>
    <arm_group_label>BI 695501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab-EU source</intervention_name>
    <description>adalimumab-EU source single s.c. injection</description>
    <arm_group_label>adalimumab-EU source</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab-US source</intervention_name>
    <description>adalimumab-US source single s.c. injection.</description>
    <arm_group_label>adalimumab-US source</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy males according to the following criteria:

          1. Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure [BP] and pulse rate [PR]), 12-lead electrocardiogram (ECG), and
             clinical laboratory tests;

          2. Age-greater than or equal to 18 years and less than or equal to 55 years;

          3. Body mass index (BMI) =18.5 to =29.9 kg/m2; and

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation.

        Exclusion criteria:

          1. Any clinically relevant abnormal finding of the medical examination (including blood
             pressure (BP), pulse rate (PR), and electrocardiogram (ECG) deviating from normal and
             of clinical relevance;

          2. Any evidence of a clinically relevant previous or concomitant disease as judged by the
             investigator including gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological, hormonal disorders, or diseases of the central nervous
             system (such as epilepsy), psychiatric disorders, or neurological disorders;

          3. History of relevant orthostatic hypotension, fainting spells, or blackouts;

          4. Chronic or relevant acute infections. A negative result for human immunodeficiency
             virus (HIV), Hepatitis B (Hep B), and hepatitis C (Hep C) is required for
             participation;

          5. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients);

          6. Intake of prescribed or over-the-counter drugs with a long half-life (greater than 24
             hours) within at least one month or at least 5 half-lives of the respective drug
             (whichever is longer) prior to administration or during the trial;

          7. Previous exposure of a biologic drug;

          8. Use of drugs which might reasonably influence the results of the trial prior to dosing
             and at any time during the trial;

          9. Intake of an investigational drug in another trial within two months prior to intake
             of study medication in this trial or intake of an investigational drug during the
             course of this trial;

         10. Smoker (greater than 10 cigarettes or greater than 3 cigars or greater than 3
             pipes/day);

         11. Inability to refrain from smoking during days of confinement at the trial site;

         12. History of alcohol abuse (estimated average more than 4 units/day);

         13. Unwillingness/inability to refrain from intake of alcoholic beverages from 48 hours
             prior to the study medication administration and until Day 7 post study medication
             administration;

         14. Unwillingness/inability to limit alcohol intake to a maximum of three units per day
             until e.o.s.;

         15. Current drug abuse;

         16. Blood donation (more than 100 mL within four weeks prior to administration of the
             study medication or during the trial);

         17. Vigorous exercise 72 hours prior to dosing. Unwilling to avoid vigorous exercise for 7
             days post dosing. Contact sport should be avoided during the entire study;

         18. Any out-of-range laboratory values considered clinically significant by the
             investigator; subjects with creatine kinase (CK) values three times the upper limit of
             normal (ULN) at Day -1 are excluded from participation;

         19. Subjects considered unsuitable for inclusion by the investigator (e.g., inability to
             understand and comply with the study requirements or presence of any condition which,
             in the opinion of the investigator, would not allow safe participation in the study);
             or

         20. Inability to comply with dietary regimen of trial site.

         21. Subjects with known Human immunodeficiency virus (HIV), Acquired Immunodeficiency
             Syndrome, other clinically significant immunological disorders, or auto-immune
             disorders, (e.g., Rheumatoid arthritis (RA), lupus erythematosus, scleroderma, etc.);

         22. Subject has received a live or attenuated vaccine within 12 weeks prior to enrolling
             in the trial; or

         23. Positive finding in Interferon-gamma-release assay testing (IGRA-T). In cases where at
             the screening visit the IGRA result is indeterminate, the subject will have a PPD skin
             test performed, provided that the screening period timeframe can be maintained. If
             not, the subject will not be enrolled in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1297.8.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1297.8.2001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1297.8.2002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <results_first_submitted>September 11, 2017</results_first_submitted>
  <results_first_submitted_qc>September 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2018</results_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this trial 324 healthy subjects were randomized into 3 arms.</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in the trial. Subjects attended specialist sites which would then ensure that they (the subject) met all strictly implemented inclusion/exclusion criteria. Subjects were not randomised to trial treatment if any one of the specific entry criteria were violated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BI 695501</title>
          <description>Subject to receive a single subcutaneous (s.c.) injection from a prefilled syringe containing 40 milligram (mg)/0.8 millilitre (mL) BI 695501 solution.</description>
        </group>
        <group group_id="P2">
          <title>US-licensed Humira®</title>
          <description>Subject to receive a single subcutaneous (s.c.) injection from a prefilled syringe containing 40 mg/0.8 mL US-licensed Humira®</description>
        </group>
        <group group_id="P3">
          <title>EU-approved Humira®</title>
          <description>Subject to receive a single subcutaneous (s.c.) injection from a prefilled syringe containing 40 mg/0.8 mL European Union (EU)-approved Humira®.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108">1 subject (not included to the 108) was randomized but did never take any study medication.</participants>
                <participants group_id="P2" count="108">1 subject (not included to the 108) was randomized but did never take any study medication..</participants>
                <participants group_id="P3" count="108">1 subject (not included to the 108) was randomized but did never take any study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Informed Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set consisted of all subjects who received the single dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>BI 695501</title>
          <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
        </group>
        <group group_id="B2">
          <title>US-licensed Humira®</title>
          <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
        </group>
        <group group_id="B3">
          <title>EU-approved Humira®</title>
          <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="324"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="11"/>
                    <measurement group_id="B2" value="31" spread="11"/>
                    <measurement group_id="B3" value="30" spread="12"/>
                    <measurement group_id="B4" value="31" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®.
Abbreviation used: Pharmacokinetics (PK).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
        <population>PK analysis set consisted of all randomized subjects who received the single dose of trial medication (BI 695501, US-licensed - or EU-approved Humira®), had at least one evaluable primary PK endpoint and were without important protocol deviations or violations thought to significantly affect the PK of BI 695501, US-licensed - or EU-approved Humira®</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira®.
Abbreviation used: Pharmacokinetics (PK).</description>
          <population>PK analysis set consisted of all randomized subjects who received the single dose of trial medication (BI 695501, US-licensed - or EU-approved Humira®), had at least one evaluable primary PK endpoint and were without important protocol deviations or violations thought to significantly affect the PK of BI 695501, US-licensed - or EU-approved Humira®</population>
          <units>microgram (µg)*hour (h)/millilitre (mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2630" spread="52.4"/>
                    <measurement group_id="O2" value="2470" spread="51.2"/>
                    <measurement group_id="O3" value="2650" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 percent (%).</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>108.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.50</ci_lower_limit>
            <ci_upper_limit>119.79</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>101.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.45</ci_lower_limit>
            <ci_upper_limit>110.94</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>94.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.01</ci_lower_limit>
            <ci_upper_limit>102.78</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve from time zero to last measurable concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve from time zero to last measurable concentration (AUC0-tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2440" spread="47.8"/>
                    <measurement group_id="O2" value="2300" spread="45.1"/>
                    <measurement group_id="O3" value="2480" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>107.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.49</ci_lower_limit>
            <ci_upper_limit>116.94</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>99.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.15</ci_lower_limit>
            <ci_upper_limit>108.37</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>93.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.76</ci_lower_limit>
            <ci_upper_limit>101.11</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Maximum concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Maximum concentration (Cmax) of BI 695501, US-licensed Humira® or EU-approved Humira®.</description>
          <population>The PK analysis set.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.907" spread="34.1"/>
                    <measurement group_id="O2" value="3.900" spread="34.5"/>
                    <measurement group_id="O3" value="4.140" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>100.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.15</ci_lower_limit>
            <ci_upper_limit>106.88</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>96.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.06</ci_lower_limit>
            <ci_upper_limit>102.03</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PK similarity of the two treatments was to be concluded if the 90% CI for the ratio of adjusted geometric means was within 80.00 - 125.00 %.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>95.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.83</ci_lower_limit>
            <ci_upper_limit>101.33</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to 168 hours post dose (AUC 0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168 hours post dosing</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to 168 hours post dose (AUC 0-168) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480" spread="41.1"/>
                    <measurement group_id="O2" value="493" spread="40.7"/>
                    <measurement group_id="O3" value="513" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% Confidence Interval (CI) for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>98.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.54</ci_lower_limit>
            <ci_upper_limit>105.55</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>96.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.27</ci_lower_limit>
            <ci_upper_limit>103.36</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>98.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.42</ci_lower_limit>
            <ci_upper_limit>105.27</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to 312 hours post dose (AUC 0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312 hours post dosing</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to 312 hours post dose (AUC 0-312) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="957" spread="36.5"/>
                    <measurement group_id="O2" value="967" spread="34.9"/>
                    <measurement group_id="O3" value="1010" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>99.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.66</ci_lower_limit>
            <ci_upper_limit>105.94</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>97.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.39</ci_lower_limit>
            <ci_upper_limit>103.35</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>97.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.58</ci_lower_limit>
            <ci_upper_limit>103.68</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to 480 hours post dose (AUC 0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480 hours post dosing</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to 480 hours post dose (AUC 0-480) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1400" spread="35.8"/>
                    <measurement group_id="O2" value="1390" spread="32.2"/>
                    <measurement group_id="O3" value="1440" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>101.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.45</ci_lower_limit>
            <ci_upper_limit>107.36</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>98.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.27</ci_lower_limit>
            <ci_upper_limit>104.72</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>98.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.15</ci_lower_limit>
            <ci_upper_limit>103.11</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to 648 hours post dose (AUC 0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648 hours post dosing</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to 648 hours post dose (AUC 0-648) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation for Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1730" spread="37.0"/>
                    <measurement group_id="O2" value="1680" spread="33.2"/>
                    <measurement group_id="O3" value="1760" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>103.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.47</ci_lower_limit>
            <ci_upper_limit>110.29</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>100.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.37</ci_lower_limit>
            <ci_upper_limit>106.29</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>97.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.07</ci_lower_limit>
            <ci_upper_limit>102.24</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to 1032 hours post dose (AUC 0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira® PK is the abbreviation for Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032 hours post dosing</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to 1032 hours post dose (AUC 0-1032) of BI 695501, US-licensed Humira® or EU-approved Humira® PK is the abbreviation for Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2190" spread="41.4"/>
                    <measurement group_id="O2" value="2080" spread="38.5"/>
                    <measurement group_id="O3" value="2210" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>106.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.07</ci_lower_limit>
            <ci_upper_limit>114.63</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>100.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.24</ci_lower_limit>
            <ci_upper_limit>108.12</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>95.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.53</ci_lower_limit>
            <ci_upper_limit>101.60</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-∞,Obs of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
        <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) based on the last observed concentration at time of last measureable concentration (tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation of Pharmacokinetic(s).</description>
        <time_frame>at -1 hour (h) (pre dosing) and 1h, 4, 8, 12, 24, 48, 72, 84, 96, 108, 120, 132, 144, 168, 192, 240, 312, 480, 648, 1032, 1320 h post dosing and on day 71 post dosing.</time_frame>
        <population>The PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-∞,Obs of BI 695501, US-licensed Humira® or EU-approved Humira®</title>
          <description>Area under the concentration time curve (AUC) from time zero to infinity (AUC 0-∞) based on the last observed concentration at time of last measureable concentration (tz) of BI 695501, US-licensed Humira® or EU-approved Humira®.
PK is the abbreviation of Pharmacokinetic(s).</description>
          <population>The PK analysis set.</population>
          <units>µg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2630" spread="52.6"/>
                    <measurement group_id="O2" value="2470" spread="51.3"/>
                    <measurement group_id="O3" value="2640" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>108.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.54</ci_lower_limit>
            <ci_upper_limit>119.90</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>101.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.51</ci_lower_limit>
            <ci_upper_limit>111.05</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing; two-sided 90% CI for the ratio of adjusted geometric means was calculated.</non_inferiority_desc>
            <param_type>ratio of the geometric means</param_type>
            <param_value>94.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.01</ci_lower_limit>
            <ci_upper_limit>102.82</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) model on the logarithmic scale with fixed effects for treatment and trial site as well as age (as recorded at the time of informed consent) and body weight (as recorded at baseline) as continuous covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (Proportion) of Subjects With Drug Related Adverse Events</title>
        <description>All events with an onset after the first administration of the trial medication up to a period of 70 days after the last administration of the trial medication (i.e., end of the REP) was assigned to the treatment phase for evaluation and was defined as a treatment-emergent AE (TEAE). A treatment-related AE was defined as any TEAE assessed by the investigator as related to the trial medication.
All safety data were displayed and analyzed using descriptive statistical methods. No formal inferential analyses were planned for safety comparisons. Tabulations of frequencies and proportions, as appropriate were used for the evaluation of categorical (qualitative) data, and tabulations of descriptive statistics were used to analyze continuous (quantitative) data.</description>
        <time_frame>Day 1 through Day 71</time_frame>
        <population>The safety analysis set consisted of all subjects who received the single dose of trial medication (BI 695501, US-licensed Humira® or EU-approved Humira®).</population>
        <group_list>
          <group group_id="O1">
            <title>BI 695501</title>
            <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
          </group>
          <group group_id="O2">
            <title>US-licensed Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
          </group>
          <group group_id="O3">
            <title>EU-approved Humira®</title>
            <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
          </group>
        </group_list>
        <measure>
          <title>Number (Proportion) of Subjects With Drug Related Adverse Events</title>
          <description>All events with an onset after the first administration of the trial medication up to a period of 70 days after the last administration of the trial medication (i.e., end of the REP) was assigned to the treatment phase for evaluation and was defined as a treatment-emergent AE (TEAE). A treatment-related AE was defined as any TEAE assessed by the investigator as related to the trial medication.
All safety data were displayed and analyzed using descriptive statistical methods. No formal inferential analyses were planned for safety comparisons. Tabulations of frequencies and proportions, as appropriate were used for the evaluation of categorical (qualitative) data, and tabulations of descriptive statistics were used to analyze continuous (quantitative) data.</description>
          <population>The safety analysis set consisted of all subjects who received the single dose of trial medication (BI 695501, US-licensed Humira® or EU-approved Humira®).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 (first administration of trial medication) until day 71</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BI 695501</title>
          <description>single s.c. injection 40 mg/0.8 mL BI 695501 solution.</description>
        </group>
        <group group_id="E2">
          <title>US-licensed Humira®</title>
          <description>single s.c. injection 40 mg/0.8 mL US-licensed Humira®</description>
        </group>
        <group group_id="E3">
          <title>EU-approved Humira®</title>
          <description>single s.c. injection 40 mg/0.8 mL EU-approved Humira®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

